BidaskClub cut shares of Atara Biotherapeutics (NASDAQ:ATRA) from a hold rating to a sell rating in a research report released on Friday.
Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded Atara Biotherapeutics from a hold rating to a sell rating in a research note on Friday, August 3rd. Jefferies Financial Group reissued a buy rating and set a $45.00 price target on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $47.80.
NASDAQ ATRA traded up $0.88 during mid-day trading on Friday, hitting $36.42. The stock had a trading volume of 389,844 shares, compared to its average volume of 722,945. Atara Biotherapeutics has a 52-week low of $12.65 and a 52-week high of $54.45. The company has a market capitalization of $1.87 billion, a P/E ratio of -9.11 and a beta of 2.54.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.17). Equities research analysts anticipate that Atara Biotherapeutics will post -4.58 earnings per share for the current year.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction on Friday, October 5th. The stock was sold at an average price of $40.22, for a total transaction of $313,716.00. Following the completion of the transaction, the chief executive officer now owns 733,285 shares of the company’s stock, valued at $29,492,722.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Christopher Haqq sold 775 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $37.54, for a total value of $29,093.50. Following the transaction, the executive vice president now directly owns 331,355 shares of the company’s stock, valued at approximately $12,439,066.70. The disclosure for this sale can be found here. Insiders have sold 93,575 shares of company stock valued at $3,633,158 in the last three months. 10.60% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in shares of Atara Biotherapeutics in the first quarter valued at $107,000. Great West Life Assurance Co. Can grew its position in shares of Atara Biotherapeutics by 100.1% in the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 1,655 shares during the period. Bank of Montreal Can purchased a new stake in shares of Atara Biotherapeutics in the second quarter valued at $180,000. Highland Private Wealth Management purchased a new stake in shares of Atara Biotherapeutics in the second quarter valued at $202,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Atara Biotherapeutics in the first quarter valued at $214,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.